Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Lead Sponsor

Novo Nordisk A/S

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

No

•1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•2. The decision to initiate treatment with commercially available Sogroya® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. Both GH treatment naïve and non-naïve children are eligible.
•3. Male or female age 0 to 18 years (exclusive) at the time of signing informed consent.
•4. Diagnosis with short stature due to GHD where epiphysial discs are not closed according to local normal clinical practice.

•1. Previous participation in this study. Participation is defined as having given informed consent in this study.
•2. Treatment with any investigational drug within 30 days prior to baseline (the starting date of Sogroya® treatment).
•3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•4. Contraindication described in approved product labelling in Japan.
•1. Patients with hypersensitivity to the active substance or to any of the excipients
•2. Patients with malignant tumour
•3. Female patients who are either pregnant or likely to be pregnant

Related studies

NCT04970654 · Growth Hormone Deficiency in Children

NCT01514500 · Growth Hormone Disorder, Adult Growth Hormone Deficiency, and more

NCT03186495 · Growth Hormone Disorder, Adult Growth Hormone Deficiency, and more

NCT00960128 · Growth Hormone Disorder, Growth Hormone Deficiency in Children, and more

NCT01245374 · Growth Hormone Disorder, Growth Hormone Deficiency in Children, and more